182 related articles for article (PubMed ID: 28548078)
1. Associated Variables of Myositis in Systemic Lupus Erythematosus: A Cross-Sectional Study.
Liang Y; Leng RX; Pan HF; Ye DQ
Med Sci Monit; 2017 May; 23():2543-2549. PubMed ID: 28548078
[TBL] [Abstract][Full Text] [Related]
2. The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study.
Liang Y; Leng RX; Pan HF; Ye DQ
Rheumatol Int; 2017 Feb; 37(2):305-311. PubMed ID: 27999942
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical significance of lymphadenopathy and its histological subtypes in patients with systemic lupus erythematosus: a retrospective cohort study.
Papachristodoulou E; Graef E; Magliulo D; Kyttaris V
Rheumatol Int; 2023 Jul; 43(7):1277-1286. PubMed ID: 37097329
[TBL] [Abstract][Full Text] [Related]
4. Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients.
Xu SZ; Yan Liang ; Li XP; Li XM; Shuai ZW; Leng RX; Pan HF; Ye DQ
Clin Rheumatol; 2018 Jun; 37(6):1547-1553. PubMed ID: 29520672
[TBL] [Abstract][Full Text] [Related]
5. Muscle biopsy abnormalities in systemic lupus erythematosus: correlation with clinical and laboratory parameters.
Lim KL; Abdul-Wahab R; Lowe J; Powell RJ
Ann Rheum Dis; 1994 Mar; 53(3):178-82. PubMed ID: 8154935
[TBL] [Abstract][Full Text] [Related]
6. SLE/myositis overlap: are the manifestations of SLE different in overlap disease?
Dayal NA; Isenberg DA
Lupus; 2002; 11(5):293-8. PubMed ID: 12090563
[TBL] [Abstract][Full Text] [Related]
7. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus.
Sabio JM; Vargas-Hitos J; Zamora-Pasadas M; Mediavilla JD; Navarrete N; Ramirez A; Hidalgo-Tenorio C; Jáimez L; Martín J; Jiménez-Alonso J;
J Rheumatol; 2009 Oct; 36(10):2204-11. PubMed ID: 19723903
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.
Atta MS; Lim KL; Ala'deen DA; Powell RJ; Todd I
Ann Rheum Dis; 1995 Feb; 54(2):117-24. PubMed ID: 7702398
[TBL] [Abstract][Full Text] [Related]
10. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
11. Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus.
Tselios K; Gladman DD; Su J; Urowitz MB
Lupus; 2016 Apr; 25(5):532-5. PubMed ID: 26585070
[TBL] [Abstract][Full Text] [Related]
12. SLE myopathy: a clinicopathological study.
Jakati S; Rajasekhar L; Uppin M; Challa S
Int J Rheum Dis; 2015 Nov; 18(8):886-91. PubMed ID: 25963652
[TBL] [Abstract][Full Text] [Related]
13. Myositis in systemic lupus erythematosus.
Cotton T; Niaki OZ; Zheng B; Pineau CA; Fritzler M; Vinet E; Clarke AE; Bernatsky S
Lupus; 2021 Apr; 30(4):615-619. PubMed ID: 33461416
[TBL] [Abstract][Full Text] [Related]
14. Persistent lupus activity in end-stage renal disease.
Krane NK; Burjak K; Archie M; O'donovan R
Am J Kidney Dis; 1999 May; 33(5):872-9. PubMed ID: 10213642
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
[TBL] [Abstract][Full Text] [Related]
16. Clinical and histopathological features of myositis in systemic lupus erythematosus.
Tiniakou E; Goldman D; Corse A; Mammen A; Petri MA
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35351810
[TBL] [Abstract][Full Text] [Related]
17. Effects of Disease Activity and Inflammatory Response on Hypercoagulability in Patients with Systemic Lupus Erythematosus.
Liang Y; Leng RX; Pan HF; Ye DQ
Arch Med Res; 2016 Oct; 47(7):573-579. PubMed ID: 28262199
[TBL] [Abstract][Full Text] [Related]
18. Direct antiglobulin (Coombs) test in systemic lupus erythematosus patients.
Skare T; Picelli L; Dos Santos TAG; Nisihara R
Clin Rheumatol; 2017 Sep; 36(9):2141-2144. PubMed ID: 28762061
[TBL] [Abstract][Full Text] [Related]
19. Skin signs in juvenile- and adult-onset systemic lupus erythematosus: clues to different systemic involvement.
Chottawornsak N; Rodsaward P; Suwannachote S; Rachayon M; Rattananupong T; Deekajorndech T; Asawanonda P; Chiewchengchol D; Rerknimitr P
Lupus; 2018 Nov; 27(13):2069-2075. PubMed ID: 30336755
[TBL] [Abstract][Full Text] [Related]
20. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein can reflect systemic lupus erythematosus activity.
Ahn SS; Park Y; Lee DD; Bothwell ALM; Jung SM; Song JJ; Park YB; Lee SW
Lupus; 2018 Apr; 27(5):771-779. PubMed ID: 29233037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
